In addition, a 48-week phase 2b randomized, placebo-controlled trial (involving 293 adults with obesity and biopsy-confirmed MASH and fibrosis stage F1-F3) reported that once-weekly subcutaneous survodutide at doses of 2.4 mg, 4.8 mg, or 6.0 mg was superior to placebo for histological improvement in MASH without worsening of liver fibrosis, warranting further investigation in phase 3 trials (Sanyal et al., 2024[67])
Although some studies have shown an increased risk for thyroid cancer and pancreatitis in human patients, these studies are difficult to interpret due to reporting bias, lack of controlling for other patient medical histories and comorbidities, the fact that obese people are already highly at risk for specific forms of cancer and may already have primordial tumours present when beginning medication and are likely to be taking other medication apart from GLP1R agonists as well [55]
doi: 10.1016/j.ccell.2023.02.012 46
Semaglutide injections, like Ozempic and Wegovy, typically range between $1,000 and $1,200 per month, depending on your dosage and insurance coverage
Provincial Drug Programs Several provinces list semaglutide on their public formularies for type 2 diabetes
